Compare AstraZeneca plc (AZN) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Salesforce Inc — how do they compare? AstraZeneca plc trades at $167.9 (market cap $258.92B), while Salesforce Inc trades at $236.57 (market cap $195.81B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (1.93%). Which is the better fit depends on your goals — on Pluang, investors hold AstraZeneca plc for 124 Days and Salesforce Inc for 88 Days on average.
| AZN | CRM | |
|---|---|---|
Market Cap | $258.92B | $195.81B |
Volume | 3,060,175 | 21,529,713 |
Sector | Health | Technology |
52-Week High | $209.48 | $266.23 |
52-Week Low | $147.06 | $150.12 |
Typical Hold Time | 124 Days | 88 Days |
Enterprise Value | $286.19B | $226.15B |
Dividend Yield | 1.93% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $168.59, up 1.51% over 24 hours, with strong earnings beats in recent quarters and a bullish technical signal. The company shows robust fundamentals with revenue growth to $58.74 billion in 2025 and a net income margin of 17.02%. Recent news includes FDA priority review for a rare bone disease drug and NHS approval in England for its breast cancer treatment Enhertu, though a late-stage trial failure for Etcamah in breast cancer poses a setback.
The outlook remains positive with a consensus price target of $186.67, indicating potential upside, supported by a deep pipeline and analyst buy ratings. Risks include pipeline setbacks and competitive pressures, but solid cash flow and profitability metrics provide a cushion for investors seeking growth in the healthcare sector.
Salesforce (CRM) trades at $237.63, down slightly by 0.12% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with revenue growth from $37.90B in 2025 to $43.90B projected in 2026, net income margin improving to 21.99%, and consistent earnings beats. Recent news highlights AI-driven growth potential amid sector volatility.
Outlook remains positive with a consensus price target of $271.91, implying 14% upside, supported by 76.53% analyst buy ratings. Risks include competitive pressures in AI software and macroeconomic sensitivity, but robust cash flow and strategic positioning offer resilience for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
